What do medical sources say about Sumatriptan (Imitrex, Alsuma, Onzetra Xsail, Tosymra, Zembrace SymTouch, Treximet) during pregnancy?

1st Trimester: MotherToBaby reports that studies have not found a higher chance of miscarriage or birth defects after sumatriptan use in pregnancy. The 16-year registry reported 20 major birth defects among 478 evaluable first-trimester outcomes (4.2%), but its authors said the registry was too small for firm conclusions about overall risk or rare defects. A 2024 US study found no association between triptan use and major birth defects or miscarriage, while a 2021 Quebec study found a miscarriage association for triptans as a group, not sumatriptan alone. FDA labeling reports embryo loss and fetal abnormalities in animals, findings that do not establish the same effects in people. A 2026 review says ACOG treats sumatriptan as a conditional second-line option, while the European Headache Federation includes triptans among pregnancy treatments. Ask your provider about your situation. 2nd Trimester: MotherToBaby says studies have not found a higher chance of birth defects or miscarriage with sumatriptan, but does not give a separate second-trimester conclusion. The registry counted 78 outcomes first exposed in the second trimester, and the label says the data were too limited for firm conclusions about overall malformation risk. A Norwegian cohort found more uterine atony, or poor tightening of the uterus, and blood loss after use of any triptan in the second or third trimester; it did not isolate sumatriptan. A 2024 US cohort found no association between triptan use and the outcomes it studied, but did not report a separate second-trimester estimate. FDA labeling reports embryo loss and fetal abnormalities in animal studies, and the NHS says sumatriptan may be used if needed after a doctor discusses risks and benefits. Ask your provider about your situation. 3rd Trimester: MotherToBaby says some studies suggest a small increase in preeclampsia, early birth, low birth weight, or heavy bleeding after late-pregnancy sumatriptan use, but migraine itself may explain some findings. The registry counted only 16 outcomes first exposed in the third trimester, too few for firm conclusions about late-pregnancy risk. Norwegian studies linked use of any triptan in later pregnancy to uterine atony, blood loss, or postpartum hemorrhage, but did not establish a sumatriptan-specific cause. A 2024 US cohort found no association between triptan use and the outcomes it studied, without a separate third-trimester estimate; FDA labeling also reports embryo loss and fetal abnormalities in animals. A 2026 review describes ACOG's conditional second-line recommendation, while the NHS says sumatriptan may be used if needed after a doctor discusses risks and benefits. Ask your provider about your situation.

What do medical sources say about Sumatriptan (Imitrex, Alsuma, Onzetra Xsail, Tosymra, Zembrace SymTouch, Treximet) while breastfeeding?

LactMed says sumatriptan reaches milk in small amounts, is poorly absorbed by mouth, and is a preferred triptan during breastfeeding. In a five-mother injection study, the estimated infant dose was 3.5% of the mother's weight-adjusted dose; a 2021 study reported a mean 0.7% across eight sumatriptan milk-sample sets. The FDA tablet label says there are no data on direct infant effects or milk production, and LactMed found no published infant blood levels. LactMed says effects are not expected in most infants, while the NHS and EMA advise a 12-hour pause and LactMed describes a pause as most helpful in special cases such as a preterm infant. MotherToBaby says the frequency of breast or nipple pain is unknown, but the EMA's 2025 review concluded that sumatriptan can cause rare breast pain and described reports as usually temporary. Ask your provider about your situation.

Back to search

Sumatriptan

Q: Where do sources disagree on Sumatriptan (Imitrex, Alsuma, Onzetra Xsail, Tosymra, Zembrace SymTouch, Treximet) in pregnancy or breastfeeding?

Miscarriage and pregnancy outcome estimates MotherToBaby reports that sumatriptan studies have not found an increased chance of miscarriage. The 2015 meta-analysis and 2018 prospective cohort found no association when triptan users were compared with migraine or non-migraine controls, and the 2024 US cohort found no association between triptan use and the studied outcomes. A 2021 Quebec cohort reported an association between triptan-class exposure and spontaneous abortion, with unstable estimates after accounting for maternal migraine. The 2015 meta-analysis also found an association when triptan users were compared with healthy controls rather than migraine controls. The studies use different comparison groups and outcome definitions. Most positive estimates are for all triptans, not sumatriptan alone, and migraine severity may confound the association. The findings do not establish a sumatriptan-specific cause of miscarriage or a consistent major-malformation pattern. They also do not resolve every pregnancy outcome. Retain the guidance rating and state the study disagreement.

Medication

Imitrex, Alsuma, Onzetra Xsail, Tosymra, Zembrace SymTouch, Treximet

Triptan migraine medicine

Pregnancy

The best-known sumatriptan-specific pregnancy source is the 16-year voluntary registry reported by Ephross et al. in 2014. It enrolled 680 exposed pregnancies and reported 626 sumatriptan outcomes; 20 major birth defects occurred among 478 evaluable first-trimester outcomes (4.2%, 95% CI 2.6%-6.5%). The authors found no signal of a major defect pattern, but said low enrollment and loss to follow-up prevented firm conclusions or assessment of individual rare defects. The current tablet label reports 78 outcomes first exposed in trimester 2 and 16 in trimester 3; the PubMed abstract does not give those trimester-specific counts, so they are attributed to the label. A 2010 Norwegian cohort of 69,929 pregnancies found no first-trimester association between triptans and major malformations; second- or third-trimester triptan use was associated with uterine atony (adjusted OR 1.4, 95% CI 1.1-1.8) and blood loss over 500 mL (adjusted OR 1.3, 95% CI 1.1-1.5). A 2013 Norwegian registry of 181,125 women found no malformation association, but second-trimester triptan prescriptions were associated with postpartum hemorrhage (adjusted OR 1.57, 95% CI 1.19-2.07). These were class-level results, not estimates for sumatriptan alone. A 2011 Swedish register study reported a later-pregnancy preterm-birth association for migraine medicines that included triptans or ergots (OR 1.50, 95% CI 1.22-1.84), with no certain sign of teratogenicity. A small Danish sumatriptan study from 2000 included 34 exposed pregnancies and reported higher odds of preterm birth versus migraine controls (OR 6.3, 95% CI 1.2-32.0); the authors said disease severity, confounding, or chance could explain the result. A 2015 meta-analysis of six studies, including 4,208 triptan-exposed infants, found no increased spontaneous-abortion rate versus migraine controls (OR 1.27, 95% CI 0.58-2.79), but did find an association versus healthy controls (OR 3.54, 95% CI 2.24-5.59). A 2018 German prospective cohort of 432 triptan-exposed pregnancies found no increase in spontaneous abortion versus its non-migraine comparison group (adjusted OR 1.20, 95% CI 0.9-1.7). A 2021 Quebec cohort included 526 triptan-exposed pregnancies and found an association with spontaneous abortion (adjusted OR 1.63, 95% CI 1.34-1.98); its authors said estimates were unstable after considering maternal migraine. A 2024 US cohort of 767,994 pregnancies, including 4,309 triptan exposures, found no association between triptans and the outcomes it assessed, including spontaneous abortion and major malformations. These later cohorts studied the triptan class, not sumatriptan alone. The FDA label reports embryo loss and fetal abnormalities in rats and rabbits. Human observations have not shown a consistent major-malformation pattern, but the registry and class-level observational studies cannot rule out every moderate or rare risk. A 2026 review describes ACOG's recommendation as conditional second-line use for persistent migraine not controlled by first-line agents, with very low-quality evidence. A 2026 European Headache Federation consensus lists triptans among pregnancy treatment options while also noting that reproductive evidence remains limited.

Breastfeeding

Two small human milk pharmacokinetic studies measured drug transfer, not infant health outcomes. Wojnar-Horton et al. (1996) studied five women after a 6 mg subcutaneous dose and estimated a mean relative infant dose of 3.5% (95% CI 0.3%-6.7%). Amundsen et al. (2021) studied 19 breastfeeding women overall and collected eight sumatriptan sample sets; its abstract reports a mean relative infant dose of 0.7% (range 0.2%-1.8%). LactMed reports no published infant blood levels and describes only manufacturer correspondence about three exposed infants with no reported effects. The FDA tablet label states that it has no information on milk concentrations after oral tablets and no data on direct infant effects or milk production. LactMed says poor oral absorption further lowers infant exposure and that effects are not expected in most infants. LactMed describes an 8-hour pause after a single injection as a suggestion by some authors and the manufacturer's 12-hour pause as a conservative option that may be helpful in unusual cases such as prematurity. The NHS and the 2025 EMA product-information update advise a 12-hour pause. A 2024 analysis of four pharmacovigilance databases identified 26 breastfeeding-related reports with 27 reactions involving painful breasts or nipples, painful milk ejection, or reduced milk production. These reports have no exposure denominator and do not establish incidence. The EMA's 2025 review concluded a causal relationship between sumatriptan and breast pain and recommended label changes. MotherToBaby's sheet says the frequency and medication link were not established, reflecting older wording. The EMA document also gives a 2021 milk-dose estimate that does not match the Amundsen abstract; this discrepancy is recorded in the audit report and the public summary uses the primary abstract's directly reported value.

Miscarriage and pregnancy outcome estimates

Source A says: MotherToBaby reports that sumatriptan studies have not found an increased chance of miscarriage. The 2015 meta-analysis and 2018 prospective cohort found no association when triptan users were compared with migraine or non-migraine controls, and the 2024 US cohort found no association between triptan use and the studied outcomes. (MotherToBaby: Sumatriptan fact sheet, Marchenko et al.: Pregnancy outcome following prenatal exposure to triptans, meta-analysis, Spielmann et al.: Pregnancy outcome after anti-migraine triptan use, Bérard et al.: Anti-migraine medications safety during pregnancy in the US)
Source B says: A 2021 Quebec cohort reported an association between triptan-class exposure and spontaneous abortion, with unstable estimates after accounting for maternal migraine. The 2015 meta-analysis also found an association when triptan users were compared with healthy controls rather than migraine controls. (Bérard et al.: Dihydroergotamine and triptan use during pregnancy and adverse outcomes, Marchenko et al.: Pregnancy outcome following prenatal exposure to triptans, meta-analysis)
Why they differ: The studies use different comparison groups and outcome definitions. Most positive estimates are for all triptans, not sumatriptan alone, and migraine severity may confound the association.
Other sources: The 2026 review describes ACOG's pregnancy recommendation as conditional second-line use with very low-quality evidence; the 2026 European Headache Federation consensus includes triptans among pregnancy treatment options but notes limited reproductive data. (Safety and Effectiveness of Pain Medications for Migraine Management During Pregnancy and Lactation, European Headache Federation: Sex-specific management of migraine)
What the evidence shows overall: The findings do not establish a sumatriptan-specific cause of miscarriage or a consistent major-malformation pattern. They also do not resolve every pregnancy outcome. Retain the guidance rating and state the study disagreement.

How cautious pregnancy guidance should be

Source A says: A 2026 review describes ACOG as recommending sumatriptan as a conditional second-line option for persistent migraine not controlled by first-line agents, based on very low-quality evidence. (ACOG: Headaches in Pregnancy and Postpartum guideline, Safety and Effectiveness of Pain Medications for Migraine Management During Pregnancy and Lactation)
Source B says: The 2026 European Headache Federation consensus lists triptans among pregnancy treatment options, and the NHS says sumatriptan may be used during pregnancy if needed after a doctor discusses risks and benefits. (European Headache Federation: Sex-specific management of migraine, NHS: Sumatriptan)
Why they differ: The sources weigh limited observational evidence and uncertainty differently. Their wording differs in emphasis, but none describes routine self-directed use.
What the evidence shows overall: Present ACOG's conditional second-line wording and the broader European/NHS wording without turning either into a blanket conclusion. The existing guidance rating remains appropriate.

Breastfeeding pause and infant exposure

Source A says: LactMed reports low milk levels, poor oral absorption, and no expected effects for most infants; it says an 8-hour pause after a single injection has been suggested and a 12-hour pause may be useful in unusual cases such as prematurity. (LactMed (NIH): Sumatriptan, MotherToBaby: Sumatriptan fact sheet)
Source B says: The NHS, FDA tablet label, and EMA product-information update state a 12-hour pause to reduce infant exposure; the EMA wording also says expressed milk during that interval should be discarded. (NHS: Sumatriptan, DailyMed: IMITREX sumatriptan tablets (GSK label), EMA PRAC/CMDh: Sumatriptan PSUSA scientific conclusions and product-information changes)
Why they differ: The longer pause is a precaution to reduce exposure, while LactMed emphasizes low measured transfer and the absence of reported infant effects. Direct infant outcome data are sparse.
What the evidence shows overall: State the 12-hour recommendation and attribute it, while also making clear that LactMed frames it as a conservative option rather than evidence of observed infant harm.

Breast pain reports and the 2021 milk-dose estimate

Source A says: MotherToBaby says the frequency of breast or nipple pain is unknown and that a medication cause had not been established. The Amundsen primary abstract reports a mean sumatriptan relative infant dose of 0.7% (range 0.2%-1.8%). (MotherToBaby: Sumatriptan fact sheet, Amundsen et al.: Transfer of triptans into human breast milk)
Source B says: The 2025 EMA review concluded that sumatriptan can cause breast pain and described a different relative infant dose estimate for the 2021 study. (EMA PRAC/CMDh: Sumatriptan PSUSA scientific conclusions and product-information changes)
Why they differ: The EMA review postdates MotherToBaby's fact sheet and weighs spontaneous reports, a proposed mechanism, and trial information. Its summary's milk-dose figure does not match the primary abstract, and the reason is not explained there.
What the evidence shows overall: Update the breast-pain wording to reflect the EMA conclusion and its rare-frequency category. Use the Amundsen abstract's reported dose estimate in the public summary; the alternate EMA figure is not verified against the primary abstract and is not repeated there.

Last reviewed 2026-10-16

Independent check 2026-10-16

Not yet clinician-reviewed

Ask your provider about your situation.

Similar medications

Eletriptan
Rizatriptan
Zolmitriptan

Sumatriptan

Sumatriptan — Breastfeeding

What the research shows

What's in it / what was tested

Sources disagree

Options sources describe

Beyond pregnancy

All sources

Similar medications